Drug Profile
PF 3654746
Alternative Names: PF 0354746; PF-03654746; PF-3654746Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Amides; Antihistamines; Cyclobutanes; Neuropsychotherapeutics; Pyrrolidines; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Alzheimer's disease; Attention-deficit hyperactivity disorder; Gilles de la Tourette's syndrome; Narcolepsy
Most Recent Events
- 10 May 2012 Discontinued - Phase-II for Gilles de la Tourette's syndrome in USA (PO)
- 24 Jan 2012 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (PO)
- 28 Feb 2011 Discontinued - Phase-I for Alzheimer's disease in USA (PO)